Literature DB >> 8971983

The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.

R K Schwarting1, J P Huston.   

Abstract

Lesions with the neurotoxin 6-hydroxydopamine (6-OHDA) have provided an important tool to study dopamine neurons in the brain. The most common version of such lesions is the unilateral one where the toxin is placed in the area of mesencephalic dopamine cell bodies or their ascending fibers. This approach leads to a lateralized destruction of mesencephalic dopamine neurons and to a lateralized loss of striatal dopamine innervation. Such lesions have contributed substantially to neuroscientific knowledge both, at the basic and clinical level. Physiologically, they have been used to clarify the neuroanatomy, neurochemistry, and electrophysiology of mesencephalic DA neurons and their relationships with the basal ganglia; the relevant findings have been summarized in a previous review (Schwarting, R.K.W. and Huston, J.P. (1996) Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae, Progress in Neurobiology 49, 215-266). Furthermore, 6-OHDA lesions have been used extensively to investigate the role of these dopamine neurons with respect to behavior, to examine the brain's capacity to recover from or compensate for specific neurochemical depletions, and to investigate the promotive effects of experimental and clinical approaches which are relevant for the treatment of Parkinson's disease. These findings are summarized here, including the spectrum of behavioral deficits (turning, sensory neglect, etc.), functional recovery and its possible mechanisms, the behavioral effects of widely used pharmacological challenges (amphetamines, apomorphine, selective receptor agonists, L-DOPA), and the effects of treatments which can promote recovery (like neuropeptides, neurotrophins, and grafts).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971983     DOI: 10.1016/s0301-0082(96)00040-8

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  151 in total

1.  Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ.

Authors:  E F Espejo; M C Gonzalez-Albo; J P Moraes; F El Banoua; J A Flores; I Caraballo
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

2.  Neuronal Entropy-Rate Feature of Entopeduncular Nucleus in Rat Model of Parkinson's Disease.

Authors:  Olivier Darbin; Xingxing Jin; Christof Von Wrangel; Kerstin Schwabe; Atsushi Nambu; Dean K Naritoku; Joachim K Krauss; Mesbah Alam
Journal:  Int J Neural Syst       Date:  2015-10-06       Impact factor: 5.866

3.  Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System.

Authors:  Alejandra N Martinez; Mario T Philipp
Journal:  J Neurol Neuromedicine       Date:  2016

4.  Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.

Authors:  O Sader-Mazbar; Y Loboda; M J Rabey; J P M Finberg
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 5.  A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.

Authors:  Annalisa Pinna; Micaela Morelli
Journal:  Neurotox Res       Date:  2013-12-10       Impact factor: 3.911

6.  Quantifying muscle alterations in a Parkinson's disease animal model using electromyographic biomarkers.

Authors:  Pablo Y Teruya; Fernando D Farfán; Álvaro G Pizá; Jorge H Soletta; Facundo A Lucianna; Ana L Albarracín
Journal:  Med Biol Eng Comput       Date:  2021-07-23       Impact factor: 2.602

7.  Modeling operant behavior in the Parkinsonian rat.

Authors:  Irene Avila; Mark P Reilly; Federico Sanabria; Diana Posadas-Sánchez; Claudia L Chavez; Nikhil Banerjee; Peter Killeen; Eddie Castañeda
Journal:  Behav Brain Res       Date:  2008-11-27       Impact factor: 3.332

8.  Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease.

Authors:  R K Schwarting; M Sedelis; K Hofele; G W Auburger; J P Huston
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

9.  A novel skilled-reaching impairment in paw supination on the "good" side of the hemi-Parkinson rat improved with rehabilitation.

Authors:  Patricia Vergara-Aragon; Claudia L R Gonzalez; Ian Q Whishaw
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

10.  Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.

Authors:  Vincenza Bagetta; Carmelo Sgobio; Valentina Pendolino; Giulia Del Papa; Alessandro Tozzi; Veronica Ghiglieri; Carmela Giampà; Elisa Zianni; Fabrizio Gardoni; Paolo Calabresi; Barbara Picconi
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.